丨 2026年2月25日星期三丨 NO.1 先为达生物与辉瑞中国就GLP-1药物达成合作 2月24日,“先为达生物”微信公众号发布消息,宣布与辉瑞中国就新一代偏向型GLP-1受体激动剂埃诺格鲁肽注射液达成商业化战略合作协议。先为达生物将有权获得辉瑞支付的最高可达4.95亿美元的付款总额,包括首付款、注册及销售里程碑付款。 点评:先为达生物与辉瑞中国达成商业化合作,是国产GLP-1赛道颇具分量...
Source Link丨 2026年2月25日星期三丨 NO.1 先为达生物与辉瑞中国就GLP-1药物达成合作 2月24日,“先为达生物”微信公众号发布消息,宣布与辉瑞中国就新一代偏向型GLP-1受体激动剂埃诺格鲁肽注射液达成商业化战略合作协议。先为达生物将有权获得辉瑞支付的最高可达4.95亿美元的付款总额,包括首付款、注册及销售里程碑付款。 点评:先为达生物与辉瑞中国达成商业化合作,是国产GLP-1赛道颇具分量...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.